Ursodeoxycholic acid in patients with chronic heart failure: A double-blind, randomized, placebo-controlled, crossover trial

Journal of the American College of Cardiology

Volumn 59, Issue 6, 2012, Pages 585-592

  Von Haehling, Stephan ^a,b   Schefold, Joerg C ^a   Jankowska, Ewa A ^c,d   Springer, Jochen ^a,e   Vazir, Ali ^f   Kalra, Paul R ^g   Sandek, Anja ^a   Fauler, Gnter ^h   Stojakovic, Tatjana ^h   Trauner, Michael ⁱ   Ponikowski, Piotr ^c,d   Volk, Hans Dieter ^a   Doehner, Wolfram ^a   Coats, Andrew J S ^e   Poole Wilson, Philip A ^f   Anker, Stefan D ^a,j  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c MILITARY HOSPITAL   (Poland)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j IRCCS SAN RAFFAELE PISANA   (Italy)

more..

Author keywords

blood flow; cytokines; heart failure; inflammation; ursodeoxycholic acid

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOOP DIURETIC AGENT; PLACEBO; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; URSODEOXYCHOLIC ACID; BACTERIUM LIPOPOLYSACCHARIDE; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ARM BLOOD FLOW; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART FAILURE; HUMAN; INFLAMMATION; LEG BLOOD FLOW; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; WALKING; CYTOKINE RELEASE; LIVER FUNCTION; NEW YORK HEART ASSOCIATION CLASS; PERIPHERAL CIRCULATION; PLETHYSMOGRAPHY; SIX MINUTE WALK TEST;

AGED; BILE ACIDS AND SALTS; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; EXERCISE TOLERANCE; FOLLOW-UP STUDIES; HAND; HEART FAILURE; HUMANS; INTERLEUKIN-6; LEG; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PLETHYSMOGRAPHY; PROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; URSODEOXYCHOLIC ACID;

EID: 84856438707     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.10.880     Document Type: Article

References (36)

1. S.D. Anker, S. von Haehling Inflammatory mediators in chronic heart failure: an overview Heart 90 2004 464 470 (Pubitemid 38406929)
2. S.D. Anker, M. Volterrani, K.R. Egerer Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure QJM 91 1998 199 203 (Pubitemid 28115853)
3. S. von Haehling, J.E. Morley, S.D. Anker An overview of sarcopenia: facts and numbers on prevalence and clinical impact J Cachexia Sarcopenia Muscle 1 2010 129 133
4. S. von Haehling, S.D. Anker Cachexia as a major underestimated and unmet medical need: facts and numbers J Cachexia Sarcopenia Muscle 1 2010 1 5
5. D.L. Mann, J.J. McMurray, M. Packer Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation 109 2004 1594 1602 (Pubitemid 38451714)
6. E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, J.T. Willerson Anti-TNF Therapy Against Congestive Heart Failure Investigators Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 2003 3133 3140 (Pubitemid 36793081)
7. S. von Haehling, S.D. Anker Future prospects of anticytokine therapy in chronic heart failure Expert Opin Investig Drugs 14 2005 163 176 (Pubitemid 40403390)
8. S.D. Anker, K.R. Egerer, H.D. Volk, W.J. Kox, P.A. Poole-Wilson, A.J. Coats Elevated soluble CD14 receptors and altered cytokines in chronic heart failure Am J Cardiol 79 1997 1426 1430
9. A. Sandek, J. Bauditz, A. Swidsinski Altered intestinal function in patients with chronic heart failure J Am Coll Cardiol 50 2007 1561 1569 (Pubitemid 47532323)
10. J. Niebauer, H.D. Volk, M. Kemp Endotoxin and immune activation in chronic heart failure: a prospective cohort study Lancet 353 1999 1838 1842 (Pubitemid 29251016)
11. U. Leuschner, M. Leuschner, J. Sieratzki, W. Kurtz, K. Hubner Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up A pilot study Dig Dis Sci 30 1985 642 649 (Pubitemid 15045039)
12. K. Aouad, Y. Calmus, B. Nordlinger, A. Myara, B. Weill, R. Poupon Immunosuppressive effects of endotoxins and bile acids in vivo in the rat Eur J Clin Invest 26 1996 45 48 (Pubitemid 26046787)
13. J.A. Talwalkar, K.D. Lindor Primary biliary cirrhosis Lancet 362 2003 53 61 (Pubitemid 36835823)
14. T. Ikegami, Y. Matsuzaki Ursodeoxycholic acid: mechanism of action and novel clinical applications Hepatol Res 38 2008 123 131
15. T. Iwasaki ber die Konstitution der Ursodeoxycholsure Z Physiol Chem 244 1936 181 193
16. I. Makino, K. Shinozaki, K. Yoshino, S. Nakagawa Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid Nippon Shokakibyo Gakkai Zasshi 72 1975 690 702
17. K. Dickstein, A. Cohen-Solal, G. Filippatos ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2008 2388 2442
18. P.A. Clavien, A.I. Sharara, C.A. Camargo Jr., R.C. Harland, J.G. Fitz Evidence that ursodeoxycholic acid prevents steroid-resistant rejection in adult liver transplantation Clin Transplant 10 1996 658 662 (Pubitemid 27010919)
19. G. Sderdahl, G. Nowak, F. Duraj, F.H. Wang, C. Einarsson, B.G. Ericzon Ursodeoxycholic acid increased bile flow and affects bile composition in the early postoperative phase following liver transplantation Transpl Int 11 Suppl 1 1998 S231 S238
20. J.F. Fleckenstein, M. Paredes, P.J. Thuluvath A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection Liver Transpl Surg 4 1998 276 279 (Pubitemid 28323746)
21. T. Stojakovic, C. Putz-Bankuti, G. Fauler Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid Hepatology 46 2007 776 784 (Pubitemid 47436124)
22. M. Volterrani, A.L. Clark, P.F. Ludman Predictors of exercise capacity in chronic heart failure Eur Heart J 15 1994 801 809 (Pubitemid 24205970)
23. M. Hills, P. Armitage The two-period cross-over clinical trial Br J Clin Pharmacol 8 1979 7 20 (Pubitemid 9234327)
24. J.R. Wilson, J.L. Martin, D. Schwartz, N. Ferraro Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle Circulation 69 1984 1079 1087 (Pubitemid 14108786)
25. A. Bomzon, P. Ljubuncic Bile acids as endogenous vasodilators Biochem Pharmacol 49 1995 581 589
26. L. Sinoway, J. Minotti, T. Musch Enhanced metabolic vasodilation secondary to diuretic therapy in decompensated congestive heart failure secondary to coronary artery disease Am J Cardiol 60 1987 107 111 (Pubitemid 17132115)
27. W. Doehner, N. Schoene, M. Rauchhaus Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies Circulation 105 2002 2619 2624 (Pubitemid 34596038)
28. L.A. Allen, G.M. Felker, S. Pocock Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program Eur J Heart Fail 11 2009 170 177
29. H. Shinagawa, T. Inomata, T. Koitabashi Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure Circ J 72 2008 364 369 (Pubitemid 351600627)
30. J. Sinisalo, H. Vanhanen, P. Pajunen, H. Vapaatalo, M.S. Nieminen Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease Br J Clin Pharmacol 47 1999 661 665 (Pubitemid 29257664)
31. M. Rauchhaus, W. Doehner, D.P. Francis Plasma cytokine parameters and mortality in patients with chronic heart failure Circulation 102 2000 3060 3067
32. S. Gldtuna, B. Deisinger, A. Weiss Ursodeoxycholate stabilizes phospholipid-rich membranes and mimics the effect of cholesterol: investigations on large unilamellar vesicles Biochim Biophys Acta 1326 1997 265 274 (Pubitemid 27272131)
33. R. Ninomiya, K. Matsuoka, Y. Moroi Micelle formation of sodium chenodeoxycholate and solubilization into the micelles: comparison with other unconjugated bile salts Biochim Biophys Acta 1634 2003 116 125 (Pubitemid 37487715)
34. G. Paumgartner Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets World J Gastroenterol 12 2006 4445 4451 (Pubitemid 44256328)
35. S. Bhrle, G. Szab, A. Stiehl Adjuvant treatment with ursodeoxycholic acid may reduce the incidence of acute cardiac allograft rejection J Heart Lung Transplant 17 1998 592 598 (Pubitemid 28289990)
36. C.M. Rodrigues, C.J. Steer The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent Expert Opin Investig Drugs 10 2001 1243 1253 (Pubitemid 32633568)